MultiplexDX, an innovative biotechnology company is developing accurate and affordable methods of personalised cancer diagnostics. The team, which consists of experienced, renowned scientists, won the Slovak Start-up Awards 2016 and has joined the New Europe 100: “Eastern Europe's emerging technology stars” compiled by Google and the Financial Times, among others.
Total investment volume between USD 1 and 1.3 million, equivalent of EUR 835k to 1 million
Please login or register to access more information about this investment opportunity
MultiplexDX is an innovative biotechnology company founded by an international team of renowned scientists. The Company develops products that will help improve the accuracy of cancer diagnoses, reduce the number of misdiagnoses and significantly increase the number of people who survive cancer. Already actively selling to research and medical institutions, the Company is commercialising a number of products that, together with the future product pipeline, will create the targeted Multiplex 7/8/9+ technology.
The team consists of renowned biochemistry, biology and biophysics specialists with long-term experience at leading research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies. The Scientific Advisory Board of MultiplexDX has attracted globally recognised experts from multi-disciplinary fields, including a Nobel Prize laureate.
The first products of a defined product pipeline are already being sold to major research institutions and healthcare facilities. MultiplexDX is focussing its upcoming activities to primarily increase the sale of these products. Customers include renowned companies, such as the National Institute of Health, Albert Einstein College of Medicine, University of Düsseldorf, Cornell University, Rockefeller University, and Vanderbilt University.
MultiplexDX will use the investment to boost sales of existing products and to develop and validate future products from the product pipeline.
MultiplexDX in the media: